REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading biotechnology company that realizes the promise of synthetic biology, today announced the appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. . In this process, Ms. Fitzgerald oversees the Company’s legal and compliance practices, and provides strategic direction to the Board of Directors and the executive management team. He will report directly to Dr. Stephen Dilly, President and CEO of Codexis.
“Meg is a seasoned legal administrator and leader with a deep understanding of both complex and complex legal issues,” said Dr. Dilly. “Meg brings legal and business expertise across product development, commercial launch, compliance, and intellectual property. I am excited to welcome Meg to the team. The skill set and Meg will be very important as we continue to grow our business.”
“I am delighted to be joining Codexis at this exciting time in the Company’s development and I look forward to building on the many achievements of the team,” said Ms. Fitzgerald. “Codexis is a leader in the automotive industry, and I am honored to work alongside this talented executive team as we continue to drive innovation across our core markets.”
For more than twenty years Ms. Fitzgerald’s experience spans the biotechnology industry. Most recently, he served as General Counsel, Corporate Secretary and Chief Compliance Officer at Allakos, Inc., where he provided strategic legal advice on security, litigation, IP strategy, clinical development, and marketing. Before Allakos, Ms. Fitzgerald is the Senior Vice President and Chief Privacy Officer at Aimmune Therapeutics, Inc. Pharma to AstraZeneca. Earlier in her career, Ms. Fitzgerald held senior leadership positions at Genentech, Inc., eventually serving as Deputy General Counsel and Director of Communications Law. Ms. Fitzgerald as Associate Attorney at Pillsbury Winthrop Shaw Pittman. He holds a JD from the University of California, Berkeley, and an MA and BA in history from Stanford University.
Codexis is a biotechnology company that is committed to using its proprietary CodeEvolver® platform to discover and develop novel, high-performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable production of pharmaceuticals, food, and industrial products; in the creation of new generations of life science tools; and as an anti-inflammatory and relieves mouth sores. The Company’s unique performance enzymes drive improvements such as: reducing energy use, waste generation and capital requirements; higher yield; higher fidelity analysis; and more effective medications. Codexis enzymes hold promise for synthetic biology to improve human and global health. For more information, visit www.codexis.com.
As the information contained in this press release is not a description of Codexis’ past information, it is a forward-looking statement that reflects management’s current beliefs and expectations made in accordance with the safe harbor of the Securities and Exchange Commission Amendment Act of 1995. You should not place undue reliance on these forward-looking statements because they contain known, unknown and uncertain risks and other factors are, in some cases, beyond the control of Codexis and may affect actual results. Additional information on factors affecting actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) at the Meeting -February 28, 2022 and Codexis’ Annual Report on Form 10- Filed by Q with the SEC on August 5, 2022, including under the heading “Risk Factors,” etc. Codexis report filed with the SEC. Codexis expressly disclaims any desire or obligation to update these forward-looking statements, except as required by law.
Contact Business Relations:
Brendan Strong/Carrie McKim